Viridian Therapeutics Q3 net loss more than doubles to $101.21 million

• Viridian Therapeutics’ third-quarter 2026 net loss more than doubled year over year to $101.21 million.
• Total revenues fell 64% year over year to $25.75 million.
• Lumvoa’s initial launch exceeded management’s expectations, with more than 100 patients receiving therapy by September 30.
• An elegrobart BLA submission for thyroid eye disease remains on track for the first quarter of 2027.
• Cash, cash equivalents and marketable securities totaled $955.2 million at September 30; existing funds and anticipated commercial revenues should support operations through profitability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104573611) on November 04, 2026, and is solely responsible for the information contained therein.